Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia | Zendy

Jan A. Burger | Zendy; Alessandra Tedeschi | Zendy; Paul M. Barr | Zendy; Tadeusz Robak | Zendy; Carolyn Owen | Zendy; Paolo Ghia | Zendy; Osnat Bairey | Zendy; Peter Hillmen | Zendy; Nancy L. Bartlett | Zendy; Jianyong Li | Zendy; David Simpson | Zendy; Sebastian Grosicki | Zendy; Stephen Devereux | Zendy; Helen O. McCarthy | Zendy; Steven Coutré | Zendy; Hang Quach | Zendy; Gianluca Gaïdano | Zendy; Zvenyslava Maslyak | Zendy; Don A. Stevens | Zendy; Ann Janssens | Zendy; Fritz Offner | Zendy; Jiřı́ Mayer | Zendy; Michael O’Dwyer | Zendy; Andrzej Hellmann | Zendy; Anna Schuh | Zendy; Tanya Siddiqi | Zendy; Aaron Polliack | Zendy; Constantine S. Tam | Zendy; Deepali Suri | Zendy; Mei Cheng | Zendy; Fong Clow | Zendy; Lori Styles | Zendy; Danelle F. James | Zendy; Thomas J. Kipps | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

Author(s) -

Jan A. Burger,

Alessandra Tedeschi,

Paul M. Barr,

Tadeusz Robak,

Carolyn Owen,

Paolo Ghia,

Osnat Bairey,

Peter Hillmen,

Nancy L. Bartlett,

Jianyong Li,

David Simpson,

Sebastian Grosicki,

Stephen Devereux,

Helen O. McCarthy,

Steven Coutré,

Hang Quach,

Gianluca Gaïdano,

Zvenyslava Maslyak,

Don A. Stevens,

Ann Janssens,

Fritz Offner,

Jiřı́ Mayer,

Michael O’Dwyer,

Andrzej Hellmann,

Anna Schuh,

Tanya Siddiqi,

Aaron Polliack,

Constantine S. Tam,

Deepali Suri,

Mei Cheng,

Fong Clow,

Lori Styles,

Danelle F. James,

Thomas J. Kipps

Publication year - 2015

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1509388

Subject(s) - ibrutinib , chronic lymphocytic leukemia , chlorambucil , medicine , oncology , immunosuppression , lymphocytic infiltration , leukemia , chemotherapy , cyclophosphamide

Chronic lymphocytic leukemia (CLL) primarily affects older persons who often have coexisting conditions in addition to disease-related immunosuppression and myelosuppression. We conducted an international, open-label, randomized phase 3 trial to compare two oral agents, ibrutinib and chlorambucil, in previously untreated older patients with CLL or small lymphocytic lymphoma.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research